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Modular protein engineering is suited to recruit complex and multiple functionalities in 
single-chain polypeptides. Although still unexplored in a systematic way, it is anticipated 
that the positioning of functional domains would impact and refine these activities, 
including the ability to organize as supramolecular entities and to generate multifunctional 
protein materials. To explore this concept, we have repositioned functional segments in 
the modular protein T22-GFP-H6 and characterized the resulting alternative fusions. In 
T22-GFP-H6, the combination of T22 and H6 promotes self-assembling as regular 
nanoparticles and selective binding and internalization of this material in CXCR4-
overexpressing tumor cells, making them appealing as vehicles for selective drug 
delivery. These pleiotropic activities result dramatically affected in module-swapped 
constructs, proving the need of a carboxy terminal positioning of H6 for protein self-
assembling, and the accommodation of T22 at the amino terminus as a requisite for 
CXCR4+ cell binding and internalization. Furthermore, failure of self-assembling as 
regular oligomers reduces cellular penetrability of the fusions while keeping the specificity 
of the T22-CXCR4 interaction. Altogether, these data instruct how multifunctional 
nanoscale protein carriers can be designed for smart, protein-driven drug delivery, not 
only for the treatment of CXCR4+ human neoplasias but also for the development of anti-





Protein-based drug delivery offers promises in the design of innovative drug delivery 
systems, especially when intended for precision medicines that require selective 
penetration of the therapeutic agent into target cells [1]. Proteins and peptides, over other 
materials commonly explored as drug delivery systems, offer high structural and 
functional versatility easily regulatable by genetic engineering. This flexibility allows 
generating protein materials non-existing in nature, with novel functions or combinations 
of them, for  appealing applications [2-8]. Among different strategies of protein 
engineering , modular genetic fusion permits the recruitment, in single polypeptide chains, 
of multiple biological activities [9], and their simple biological production in recombinant 
forms [10]. Such modular concept has been largely used in cancer therapies [11-13], 
where the combination of targeting and cytotoxic domains is a common issue [10, 14-18]. 
Usually, the precise order of modular placement in multifunctional proteins is based on 
trial-and-error assisted by the background about protein functionalities when amino or 
carboxy termini are blocked, as clinically relevant peptides might require free ends for 
biological functions. Examples of full structure-based rational design, although existing, 
are not abundant [9, 19-22]. Recently, we have adapted the modular protein T22-GFP-
H6 as a self-assembling protein-based tumor-targeted vehicle for pro-apoptotic factors 
[18] and for the antitumoral drug floxuridine [23]. The use of this vehicle for precision 
cancer medicine has resulted in reduced tumor volume but specially, in less metastatic 
foci in mouse models of colorectal cancer [23]. T22-GFP-H6 is produced in recombinant 
bacteria and oligomerizes into toroid nanoparticles of 12 nm (see figures 1 and 2 in [24]),.   
representing a paradigmatic example of universal transversal self-assembling protein 
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platform based on a combination of cationic peptides and polyhistidines [25]. Self-
assembling of T22-GFP-H6 requires the cationic peptide T22, a polyphemusin II-
derivative [26] that acts as a potent ligand [27, 28] of the tumoral marker CXCR4 [29]. 
Self-organization of the protein also requires a histidine rich-region (H6) responsible for 
divalent cation-mediated protein-protein interactions [30]. The optimal position of these 
functional modules has not been previously assessed, as it derives from early data 
describing the architectonic potential of cationic peptides in GFP fusions [31]. Since 
CXCR4 is overexpressed in more than 20 human neoplasias [32-37], developing optimal 
protein vehicles as CXCR4-selective drug carriers would be highly desirable. On the other 
hand, the use of histidine-rich regions as protein connectors is of obvious interest for the 
construction of tailored protein materials. In this context, we have explored the potential 
impact of modular swapping in the model T22-GFP-H6, on those properties critical for its 
role as drug vehicle, including assembling capacity, selective CXCR4-targeting and cell 
internalization. Being the properties of T22-GFP-H6 extensible to the protein self-
assembling platform irrespective of the involved functional domains, this information is of 
pivotal relevance for the further design of built-in, protein-only antitumoral drugs within 
the nanoscale for active tumor targeting [13, 14, 38]. 
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METHODS 
Genetic design, protein production and purification 
The nomenclature of the proteins has been established according to their modular 
organization. An Escherichia coli codon-optimized gene encoding H6-GFP-T22 was 
designed in house and provided by Geneart (ThermoFisher) inserted in pET22b. Details 
of the other gene fusions can be found elsewhere (see figure 1 in [30]) and the properties 
of the encoded proteins are summarized in Figure 1A. The plasmids were 
transformed in E. coli Origami B (BL21, OmpT-, Lon-, TrxB, Gor-; Novagen). All proteins 
were produced in bacterial cells cultured in Lysogenic Broth (LB) medium (supplemented 
with 100 μg/mL ampicillin, 12.5 μg/mL tetracycline and 15 μg/mL kanamycin) at 20 ºC 
overnight, upon induction with 0.1 mM of Isopropyl-β-D-thiogalactopyronaside (IPTG). 
H6-GFP-T22 gene expression was triggered with 0.1 mM IPTG during 3 h at 37 ºC, for 
an optimal yield. Bacteria cells were then harvested by centrifugation (15 min, 5,000 g) 
and resuspended in wash buffer (20 mM Tris-HCl, 500 mM NaCl, 10 mM Imidazole, pH 
= 8) in presence of protease inhibitors (Complete EDTA-free, Roche Diagnostics), before 
being disrupted in a French Press (Thermo FA-078A) by two rounds at 1,200 psi. Soluble 
fractions were collected as the supernatant after centrifugation for 45 min at 15,000g). 
Proteins were finally purified by Immobilized Metal Affinity Chromatography (IMAC) using 
HisTrap Chelating HP 1mL columns (GE Healthcare) in an ÄKTA Pure system (GE 
Healtchare). Elution was achieved by a liner gradient of elution buffer (20 mM Tris-HCl, 
500 mM NaCl, 500 mM Imidazole, pH = 8) and the recovered proteins were finally 
dialyzed against sodium carbonate with salt (166 mM NaCO3H, 333 mM NaCl, pH = 8) 
buffer and centrifuged (15 min, 15,000 g) to remove insoluble aggregates. In the case of 
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GFP-H6, plain sodium carbonate without additional salt (166 mM NaCO3H, pH = 8) buffer 
was used. 
Protein purity, integrity and concentration 
Protein purity was determined by Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) followed by Western Blot (WB) immunodetection, using 
anti-His monoclonal antibody (Santa Cruz Biotechnology). On the other hand, protein 
integrity was evaluated by Matrix-Assisted Laser Desorption Ionization Time-of-Flight 
(MALDI-TOF) mass spectrometry. The final protein concentration prior experimental was 
determined by Bradford’s assay. 
Electron microscopy 
Ultrastructural characterization of T22-GFP-H6, T22-GFP-H6 (LOOP), H6-GFP-T22, and 
GFP-H6 nanomorphometry (size and shape) was determined at nearly native state with 
field emission scanning electron microscopy (FESEM). Drops of 3 µl of samples 
diluted at 0.3 mg/mL were directly deposited on silicon wafers (Ted Pella Inc.) for 30 s, 
excess of liquid blotted, air dried, and immediately observed without coating with a 
FESEM Zeiss Merlin (Zeiss) operating at 1 kV and equipped with a high resolution in-lens 
secondary electron detector. Representative images of a general fields and nanostructure 
details were captured at two high magnifications (100,000x and 300,000x). 
In silico calculations 
UCSF Chimera software [39] was used for measuring the highest theoretical distances 
among amino acids in GFP monomers and dimers. With this purpose, 1GFL PDB 
 7 
structure was used, consisting in a dimeric structure solved by X-ray diffraction with a 
resolution of 1.9 Å [40]. The measurements serve as an idea of the nature of GFP-proteins 
building blocks based on their hydrodynamic size. 
Volume size distribution and fluorescence emission 
Volume size distribution of unassembled and assembled proteins was determined by 
Dynamic Light Scattering (DLS), at 633 nm and 25 ºC in a Zetasizer Nano ZS (Malvern 
Instruments Limited), in a ZEN2112 3 mm quartz cuvette. Measurements were done in 
triplicate for error estimation and peak values referred to the average mode of the 
populations. In order to prove their oligomeric nature, T22-GFP-H6 hydrodynamic size 
was measured after exposing the protein either to 3 % Sodium Dodecyl Sulfate (SDS) or 
Ethylenediaminetetraacetic acid (EDTA) at 1:1 molar ratio. Green fluorescence emission 
of proteins was determined at 510 nm using a Varian Cary Eclipse Fluorescence 
Spectrophtometer (Agilent Technologies) upon excitation at 488 nm. For that, all proteins 
were used at 1 mg/mL in a final volume of 100 µL.  
Cell culture and protein internalization 
HeLa CXCR4+ cells were used to study the performance of the recombinant proteins in 
vitro. HeLa cells were maintained in Eagle Minimum Essential Medium (MEM Alpha 1x 
GlutaMAXTM, Gibco®) supplemented with 10 % fetal bovine serum (Gibco®) at 37 ºC in 
a 5 % CO2 humidified atmosphere. A preliminary MTT-luci assay was done to assess lack 
of protein toxicity. Essentially, a CellTiter-Glo® Luminiscent Cell Viability Assay (Promega 
Corporation) was performed after protein exposure at 1 μM and during 48 h. as previously 
described [17]. To monitor protein internalization, HeLa cells were cultured on 24-well 
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plates at 3·104 cells/well for 24 h until reaching 70 % confluence. Proteins were incubated 
for 2 h and 24 h at different concentrations (25, 100 and 1000 nM) in presence of 
OptiPROTM Serum Free Medium (Gibco) supplemented with L-glutamine. Additionally, 
specific internalization through CXCR4 receptor was assessed adding a specific 
antagonist, AMD3100 [41, 42], which inhibits the specific interaction between T22 and 
CXCR4. This chemical compound was added at a final concentration of 10 μM (10 times 
the highest protein concentration) for 1 h prior to protein incubation [43]. After protein 
exposure, cells were detached using 1 mg/mL Trypsin-EDTA (Gibco®) for 15 min at 37 
ºC, a harsh protocol designed to remove externally attached protein [44]. Intracellular 
protein fluorescence was determined by flow cytometry using a Fluorescence Assisted 
Cell Sorting (FACS)-Canto system (Becton Dickinson) using a 15 mW air-cooled argon 
ion laser exciting at 488 nm excitation. Intracellular protein fluorescence was measured 
in duplicate for each condition. 
Confocal laser scanning microscopy 
For confocal microscopy, HeLa cells were grown on MatTek plates (MatTek Corporation) 
for 48 h (50.000 cells/well). Upon exposure to 1000 nM of protein for 24 h, cell nuclei were 
labelled with 5 μg/mL Hoechst 33342 (ThermoFisher), rendering a blue signal, and 
plasma membrane with 2.5 μg/mL CellMask™ Deep Red (ThermoFisher), rendering a 
red signal, for 10 min at room temperature. Cells were then washed in PBS buffer (Sigma-
Aldrich). Images were collected on an inverted TCS SP5 Spectral confocal microscope 
(Leica Microsystems) using 63 x (1.4 NA) oil immersion objective lenses.  Excitation was 
reached via a 405 nm blue diode laser for Hoechst 33342, 488 nm line of an argon ion 
laser for GFP and 633 nm line of a HeNe laser for CellMaskTM Deep Red. Optimized 
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emission detection bandwidths were configured to avoid inter-channel crosstalk and 
multitrack sequential acquisition settings were used. The confocal pinhole was set to 1 
Airy unit and z-stacks acquisition intervals were chosen to satisfy Nyquist sampling 
criteria. Images were processed using Imaris v 7.2.1 software (Bitplane). Three-
dimensional images were processed using the Surpass Module. 
Data analysis 
Quantitative data are expressed as mean ± standard error. Pairwise comparisons of 
conditions for each protein were made with Tukey's HSD Q-test. Significance was 





To analyze the potential impact of alternative modular arrangements and the need of 
specific end-terminal placement of specific functional domains, we have designed, 
produced and purified the fusion protein H6-GFP-T22, for comparative functional and 
structural examination with T22-GFP-H6. For a deep analysis of the impact of modular 
distribution,  we included the T22-lacking version GFP-H6 [45] (Figure 1A), and T22-GFP-
H6(LOOP), in which the hexahistidine tail is inserted into a solvent-exposed permissive 
loop of GFP [30] (Figure 1A). Like the rest of proteins, H6-GFP-T22 was efficiently 
produced in E. coli as a proteolytically stable, single protein species of expected 
molecular mass (Figure 1B, C). Importantly, being highly fluorescent (Figure 1A), this 
protein was suitable for tracking in further comparative experiments to study protein-cell 
interactions and internalization by flow cytometry and confocal microscopy. When 
determining the self-assembling properties of this new modular distribution we noted that, 
in contrast with the original T22-GFP-H6 (assembling as 12 nm- oligomers), H6-GFP-T22 
was unable to self-assemble as regular nanoparticles under the conditions that trigger the 
nanoscale organization of T22-GFP-H6 (Figure 2A, B, C). H6-GFP-T22 showed a 
hydrodynamic size (5.6 nm) compatible with the monomeric form of GFP (Figure 2D). 
GFP-H6 and T22-GFP-H6(LOOP) showed a slightly larger average particle size (6.5 nm), 
compatible with an unbalanced mixture between monomeric (5.4 nm) and dimeric forms 
(around 7.7 nm) of GFP (Figure 2D). Both the presumed dimeric forms and the multimeric 
(decameric [24]) T22-GFP-H6, were disassembled to the smaller 5.6 nm building blocks 
(Figure 2C) by either the addition of EDTA, that removes the cross-molecular interacting 
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divalent cations supportive of nanoparticle formation [30], or by the addition of the 
denaturing agent SDS. None of these proteins showed toxicity when exposed to cultured 
CXCR4+ HeLa cells (Figure 2 E). 
Irrespective of its oligomerization status, we were interested in knowing whether T22, in 
a C-terminal accommodation, would be able to recognize its CXCR4 receptor and 
promote internalization into CXCR4+ cells. The intrinsic fluorescence of H6-GFP-T22 
allowed an easy tracking of the protein in protein-exposed cells. As observed (Figure 3A), 
H6-GFP-T22 was only moderately able to penetrate CXCR4+ HeLa cells in culture in a 
time-dependent fashion, with respect to the control T22-GFP-H6. Then, it was observed 
about 5-fold less intracellular fluorescence (corrected by the specific fluorescence, and 
therefore, representative of protein amounts) than T22-GFP-H6, and 4-fold less when 
compared to T22-GFP-H6(LOOP). This profile, similar to data recorded at both 2 and 24 
h (Figure 3A), was indicative of a less efficient cell uptake of the protein mediated by the 
T22 peptide when positioned at the C terminus of the protein. This fact could be not 
straightforward accounted by the lack of assembly into nanoparticles, as T22-GFP-
H6(LOOP) was also unable to form regular oligomers (Figure 2) and it showed a cell 
penetrability potential only slightly lower than that of the parental protein (Figure 3A). The 
similar uptake of T22-GFP-H6 and T22-GFP-H6(LOOP) indicates that the position of H6, 
the protein segment responsible for oligomerization, has only a minor effect on the cell 
penetrability mediated by the N-terminal T22. This fact can be explained as an indirect 
effect because the regular multivalent presentation of the CXCR4 ligand (promoted by 
functional H6) favors cooperative cell binding and endosome formation in a virus-like 
fashion [46]. When checking whether the residual binding of H6-GFP-T22 to HeLa cells 
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was CXCR4-dependent, we noted that the specificity of T22-mediated interaction was 
also lost. At 1 µM protein concentration, the CXCR4 antagonist AMD3100 [41, 42] blocked 
the penetration of T22-GFP-H6 by about 75 %, while the uptake of H6-GFP-T22 was only 
reduced by 15 % (Figure 3B). At low protein doses, the specificity of the internalization 
process generically increased but it was still non-significant and lower in the case of H6-
GFP-T22 than when testing the parental construct (79 % versus 98 %). This indicated 
that the residual internalization of H6-GFP-T22 was mostly CXCR4-independent.  
Envisaging that this fact might also affect the intracellular localization of the protein, we 
analyzed protein-exposed HeLa cells by confocal microscopy. Indeed, while T22-GFP-
H6 and T22-GFP-H6(LOOP) distributed as a perinuclear punctuated pattern, indicative 
of an endosomal penetration route, H6-GFP-T22 fluorescence mostly accumulated at the 
cell membrane level, with a very modest true internalization (Figure 4, top). Control GFP-
H6 was not detected in cells. These patterns were fully confirmed by 3D cell imaging, that 
again supported the strong membrane association of H6-GFP-T22 (Figure 4 bottom 
Figure 5) with only limited internalization, in contrast to what happens to the proteins with 
the amino terminal T22. Since previous to flow cytometric analysis, protein-exposed cells 
were submitted to a harsh trypsin treatment to remove the externally attached protein 
[44], the detected green fluorescence (in particular the yellow merging) revealed a very 
tight interaction between the protein and cell membranes. Such interaction appeared as 
different from that promoting endosomal internalization (assumed to be CXCR4-
dependent and responsible for the recorded mild specificity), and an important fraction of 






Altogether, the set of data presented here firmly demonstrate the relevance of domain 
accommodation in modular proteins, regarding both the property to form supramolecular 
protein materials through self-assembling but also the functionality of individual functional 
modules. The combination of a cationic domain plus a histidine-rich region, surrounding 
a core scaffold protein, was revealed as a transversal protein engineering platform to 
construct functional protein-only nanoparticles for clinical applications [25]. In this context, 
this architectonic principle at the nanoscale has been adapted to develop antimicrobial 
nanoparticles [47], blood-brain-barrier crossing agents [48], CD44-targeted nanoparticles 
[49], tumor imaging agents [24], vehicles for tumor-targeted chemical drug delivery [23], 
theragnostic agents [18] and protein-only, highly cytotoxic antitumoral drugs  effective in 
colorectal cancer [50] and in acute myeloid leukemia [15]. The symmetry associated to 
the protein-assembling process, for which both a cationic peptide and a polyhistidine tail 
are required [25], is lost when the histidine-rich segment is placed in the alternative N-
terminal position or in an intermediate localization, in an overhanging loop of GFP (Figure 
2B). Also, irrespective of the formation of nanoparticles from protein building blocks, T22, 
strongly cationic, is fully functional at the N terminus but not in the C terminus (Figure 3), 
where this peptide is not able to specifically and effectively promote protein internalization 
through the cell surface receptor CXCR4. At high concentrations (Figure 3B), T22 seems 
to act as still inefficient cell-penetrating cationic peptide, with untargeted cell penetrability 
[51]. The higher penetrability of T22-GFP-H6 compared with that of T22-GFP-H6(LOOP) 
(Figures 3, 4 and 5) can be accounted by the multivalent attachment of the first construct, 
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that is expected to favor cooperativity in both binding and endosomal mediated 
internalization, compared with that of monomers and dimers formed by T22-GFP-
H6(LOOP) [46]. Finally, a free amino terminus of T22 is the requirement for a proper 
association with CXCR4. This might be related to the fact that the N-terminal repeat Tyr-
Arg-Lys in T22 is highly associated with the antiviral activity of the peptide, that is based 
on the blockage of HIV binding to CXCR4 [52]. A failure in T22-CXCR4 interaction by a 
wrong positioning of T22 in the fusion protein aborts the selectivity of the ligand by its 
cellular receptor and conduces to an unspecific and inefficient binding to cells, that 
precluded endosomal internalization (Figures 3, 4 and 5). As CXCR4 is not only a relevant 
and transversal tumoral marker but a key receptor in HIV infection, and T22 is a useful 
antagonist in the infection process [26-28], reaching a rationale for a proper T22 
positioning in potential antiviral drugs is of wider interest in the development of antitumoral 
drugs and therapeutic strategies.   
 
CONCLUSIONS 
We have determined here that the peptide H6 is a potent architectonic tag that allows the 
controlled oligomerization of recombinant fusion proteins. Moreover, this segment is only 
active when displaying a free carboxy terminus, but not when displaying the amino 
terminus or in absence of free termini. Besides this, the potent ligand of CXCR4, the 
peptide T22, promotes efficient CXCR4+ cell binding and internalization through its free 
amino terminal end. Although the nanoscale oligomerization supported by a properly 
accommodated H6 clearly favors CXCR4-dependent cell internalization, the requirement 
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of a free amino terminal end of T22 is irrespective of the protein oligomerization as regular 
nanoparticles. Sustained by the growing interest in protein-only smart materials with 
clinical applicability, these findings offer relevant clues for the development of transversal 







Figure 1. Properties of building blocks and protein nanoparticles. A. Modular 
organization of the multifunctional proteins used in the study. Segment sizes are 
indicative. Protein names are according the order of modules in the constructs. T22-GFP-
H6(LOOP) refers to the insertion of H6 into a solvent-exposed permissive loop of GFP. 
Theoretical molecular masses are indicated in KDa, as well as the specific fluorescence 
(FU) relative to T22-GFP-H6.  B. Protein purity upon purification, shown by SDS-PAGE, 
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demonstrating their proteolytic stability as single molecular mass species. M in the image 
indicates the molecular marker lane, showing the molecular masses in KDa. C. Mass 
spectrometry of the same protein samples. 
 
Figure 2. Protein assembly as oligomeric nanoparticles. A. Representative FESEM 
images of the GFP-based recombinant proteins upon purification. Bars indicate 30 nm. 
B. Hydrodynamic size of unassembled proteins and protein nanoparticles, indicating the 
peak size of DLS plots and the polydispersion index (PDI). C. Controlled disassembly of 
T22-GFP-H6 nanoparticles mediated by 3 % SDS or by EDTA at 1:1 molar ratio related 
to His residues. D. Molecular modelling of native GFP showing both the monomeric and 
dimeric forms and their larger atomic distances. E. MTT cell viability analysis of HeLa 
cells exposed to pure proteins (at 1000 nM) for 48 h. Data are referred to the viability of 




Figure 3. Efficacy and specificity of cell penetrability of protein nanoparticles. A. 
Internalization of T22-GFP-H6, T22-GFP-H6(LOOP), H6-GFP-T22 and GFP-H6 in 
CXCR4+ HeLa cells, recorded after 2 h and 24 h of exposure, at three different 
concentrations (25 nM, 100 nM and 1000 nM). Crude fluorescence values were 
normalized by the specific fluorescence emission of each protein to allow molar-based 
comparison. Y-axis in arbitrary units of fluorescence (a.u.). Significant differences with 
T22-GFP-H6 internalization under the same conditions (included as a control) are 
represented by * (p < 0.001). B. Relative intracellular fluorescence values (a.u.) for each 
protein under prior treatment of CXCR4+ HeLa cells with AMD3100, a specific inhibitor of 
T22-CXCR4 binding, compared to those obtained at the same conditions in absence of 
this compound. The analysis was done 2 h after exposure. Significant difference with 
protein internalization under the same conditions but without AMD3100 are represented 




Figure 4. Intracellular localization of proteins in protein-exposed cells. 2D confocal 
imaging of protein-exposed HeLa cells. 
Red signal indicates labelled membranes, blue signal labelled nuclear nucleic 
acids and the green signal is the natural green fluorescence of proteins. Cells cultured in 
absence of proteins are also shown for a clear visualization of blue and red signals in 
absence of protein. At the bottom, 3D Imaris reconstruction of confocal stacks along the 
z axis of the same experiments. Analysis was performed after 24 h of protein exposure 
at 1 μM. Bars indicate 10 μm. 
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Figure 5. Intracellular and membrane localization of proteins in protein-exposed 
cells. Fine details of 3D Imaris reconstructions of confocal stacks along the z axis, 
showing the green fluorescent material. Cells cultured in absence of proteins are also 
shown. Red signal indicates labelled membranes and blue signal labelled nuclear nucleic 
 21 
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